

**University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
October 14, 2025**

Members attending the meeting: Bieniek, Kevin; Burgin, Tiffani; Chatterjee, Bandana; Chen, Ching-Kang Jason; Chen, Chun-Liang; Dell, Shelbie; Ginsburg, Brett; Gould, Georgianna; Martinez-Sobrido, Luis; Paukert, Martin; Prewit, Egle; Salamango, Daniel; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Macias, Dorothy (alternate for Cerecero, Jennifer - voting)

Guests Present: Rincon, Erica; Barlett, Emily; Vasquez, Rebecca.

Absent members: Cerecero, Jennifer; Dallas, Steven; Gauduin, Marie Claire; Mishra, Bibhuti; Shio, Yuzuru; Bloodworth, Rebecca.

1. Panel Chair Announcement

The meeting was called to order at 11:01 a.m. by the IBC Chair, Dr. Yan Xiang.

2. Confidentiality of Panel Proceedings and Conflict of Interest

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. Approval of minutes from the previous meeting

The Committee approved the minutes as written from the September 09, 2025, IBC meeting.

Approved (16 voted to approve, 0 opposed, 0 abstained)

4. Review of Approved Protocols- The spreadsheet of FY2026 approved protocols will be sent out for review in December 2025.

5. Old Business –

6. Educational Items – None

7. Occupational Medicine- As of October 1, 2025, there were 9 needlesticks, 6 were UT Health Staff/Employee, and 3 were UT students. There were 6 exposures to TB; 3 were UT Health staff/Employees, and 3 were UT students. There were 8 exposures of Bloodborne Pathogens, 2 were by UT

Health staff/employees, and 6 were by UT Health students. There was one incident of a fall involving a UT Health staff member.

8. Other – None

9. Review of EHS Assistant-

Review any issues with the EH&S Assistant program.

10. Meeting Reminder

The next meeting will be held on November 11, 2025.

Protocols for Review

11. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000020773

Principal Investigator: Gould, Georgianna; Cellular & Integrative Physiology

Title: N/A

Review Type: Full Committee Review

Form Type: Renewal

Approved (16 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with Adipose-derived Mesenchymal stem cells at BSL-2 containment.

Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

12. Presentation, Discussion, and Voting on an Initial Protocol:

Protocol ID: 0000020607

Principal Investigator: Lodge, Daniel; Pharmacology

Title: N/A

Review Type: Full Review

Form Type: Initial

Approved (16 voted to approve, 0 opposed, 0 abstained)

Initial application to work with human cell lines (HEK293T, HEK293), CHO cell lines, vectors (pRP[EXP]-CMV>{Base}, pPB[EXP]-Neo-CMV>GPCR, pRP[EXP]-CMV>Gal6), and PiggyBac transposon system at BSL-2 containment. Work with proteins (GPR26, GPR85, OGR1) at BSL-1 containment.

Protocol does include the use of recombinant DNA.

This protocol was approved with clarification.

1. The committee requested clarifications on the transportation of samples.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

13. Presentation, Discussion, and Voting on an Amendment Protocol:

Protocol ID: 0000020533

Principal Investigator: Rasmussen, Blake; Cellular & Integrative Physiology

Title: N/A

Review Type: Full Review

Form Type: Amendment

Approved (16 voted to approve, 0 opposed, 0 abstained)

Amendment application, to work with human cell lines (HFF, MDA-231, HEK293/YAP1) at BSL-2 containment.

Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4

14. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000020422

Principal Investigator: Xiang, Yan; Microbiology, Immunology & Molecular Genetics

Title: N/A.

Review Type: Full Review

Form Type: Renewal

Approved (16 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with SARS-CoV2, SARS-CoV2 mouse-adapted, SARS-CoV2 hCov-19/USA/CA/CDC5574/2020, SARS-CoV2 South Africa/K005321/2020, and SARS-CoV2 South

Africa/K005325/2020 at BSL-3 containment. They will also work with Vaccinia virus (MVA) and human cell lines (LA-4, LLC1, Calu-1, Huh7, Vero) at BSL-2 containment.
Work with CCR10 at ABSL-1 containment. IACUC# 2020048X.

In vivo:

Work with SARS-CoV-2 and SARS-CoV-2 mouse-adapted in mice at ABSL-3 containment.
IACUC# 210084X, #20220048, 2020056AR.

Work with SARS-CoV2, SARS-CoV2 hCov-19/USA/CA/CDC5574/2020, SARS-CoV2 South Africa/K005321/2020, SARS-CoV2 South Africa/K005325/2020 in hamsters at ABSL-3 containment.
IACUC# 210084X, #20220048, 2020056AR.

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F

Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4

Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

15. Presentation, Discussion, and Voting on an Amendment Protocol:

Protocol ID: 0000020539

Principal Investigator: Lawrenson-Gayther, Kate; Obstetrics/Gynecology

Title: “Novel Therapeutic Targets for Lethal Prostate Cancer Identified Through Induced Pluripotent Stem Cell (iPSC) Modelling of BRCA2mut Prostate Tissues.”

“Disordered Differentiation of Tubal Epithelia: Setting the Stage for Neoplastic Transformation.”

“A Multifaceted Approach to Biomarker Discovery for BRCA-Associated Fallopian Carcinoma.”

Review Type: Full Review

Form Type: Amendment

Approved (16 voted to approve, 0 opposed, 0 abstained)

Amendment application, to work with iPSC Prostate spheroids mixed with rat Seminal vesicle (SV) mesenchyme cells at BSL-2 containment. Work with rat primary cells and neonatal seminal vesicle (SV) mesenchyme cells at BSL-1 containment.

In vivo:

Work with rat primary cells in mice at ABSL-1 containment.
IACUC# IAMEND20250000330.

Work with iPSC Prostate spheroids mixed with rat Seminal vesicle (SV) mesenchyme cells in mice at ABSL-1 containment.

IACUC# IAMEND20250000330.

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F


Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4

Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

Adjourn: The meeting adjourned at 11:41 A.M.



Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio



Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam